SBIR/STTR Research Award

A facile approach for preparing dual agonists with long lifetimes and balanced activities

Award identifier 2186a65fe38e9a9c7ad3d5284bcec88ebf2a43051ae58f98fb465cae5749f0a7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,575

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PROLYNX, LLC
Proposal award date
2017-09-20
Contract end date
2019-09-17
UEI
NX3UG3XD7PF1
Solicitation number
PA16-302
Topic code
200

Research abstract

We have developed a chemically controlled ultra long acting delivery system to support once weekly to once monthly administration of peptides In this system the peptide is covalently attached to a hydrogel microsphere depot by a cleavable eliminative linker upon subcutaneous injection the linker slowly cleaves and releases the drug If the same linker is used to attach two different peptides to microspheres they will be released at the same rate the relative amounts released can be controlled by the relative amounts attached to the microspheres Hence this delivery system should be capable of coordinating the pharmacokinetics of dual agonists This Phase I proposal seeks to demonstrate the feasibility of utilizing a two drug delivery system to coordinate the pharmacokinetics of two peptide therapeutics We will attach both the GLP receptor agonist exenatide and a newly discovered glucagon agonist to our hydrogel microspheres using a single linker having a half life of about one week After subcutaneous injection of the microspheres in the mouse we will determine the pharmacokinetics of both these peptides Concurrently we will utilize the DIO mice as a model for obesity and attempt to demonstrate the efficacy of the dual agonist as an anti obesity drug as well as the optimal ratio of the two drugs We have developed a technology platform for half life extension that is chemically controlled by a linker used to connect the drug to a carrier We propose that by using the same linker to attach two different drugs to the same carrier we can confer the same half life to both drugs and coordinate their in vivo concentrations We will develop these concepts and apply them to produce a peptidic dual agonist for treatment of diabetes and obesity

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2010–2020). Reported award amounts total $1,581,832. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.